Carboplatin/Paclitaxel + Pembrolizumab
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Urologic Neoplasms
Conditions
Urologic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases, Penile Cancer, Penile Squamous Cell Carcinoma, Locally Advanced Penile Carcinoma
Trial Timeline
Aug 13, 2024 → Jan 14, 2028
NCT ID
NCT06353906About Carboplatin/Paclitaxel + Pembrolizumab
Carboplatin/Paclitaxel + Pembrolizumab is a phase 2 stage product being developed by Merck for Urologic Neoplasms. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06353906. Target conditions include Urologic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases.
What happened to similar drugs?
0 of 1 similar drugs in Urologic Neoplasms were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06353906 | Phase 2 | Recruiting |
Competing Products
16 competing products in Urologic Neoplasms
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| pemetrexed + cisplatin | Eli Lilly | Phase 1/2 | 32 |
| Mirabegron + Solifenacin succinate + Placebo | Astellas Pharma | Phase 2 | 35 |
| Mirabegron + Solifenacin succinate | Astellas Pharma | Phase 3 | 40 |
| Gemcitabine | Eli Lilly | Phase 2 | 35 |
| pemetrexed | Eli Lilly | Phase 2 | 35 |
| ALIMTA + gemcitabine | Eli Lilly | Phase 2 | 35 |
| BBI503 | Sumitomo Pharma | Phase 2 | 27 |
| Pembrolizumab Injection [Keytruda] | Merck | Phase 2 | 42 |
| zoledronic acid | Novartis | Phase 2 | 27 |
| mycophenolate mofetil | Roche | Phase 1 | 29 |
| Cetuximab + Paclitaxel | Bristol Myers Squibb | Phase 2 | 35 |
| Nivolumab + Relatlimab | Bristol Myers Squibb | Phase 2 | 42 |
| CBT101 + Placebo | Brain Biotech | Phase 1 | 26 |
| OGX-427 600 mg + OGX-427 1000 mg + Placebo + Gemcitabine + Cisplatin + Carboplatin | Achieve Life Sciences | Phase 2 | 25 |
| S-8184 Paclitaxel Injectable Emulsion + Experimental Arm: TOCOSOL Paclitaxel | Achieve Life Sciences | Phase 2 | 25 |
| Stem Cell | Brain Biotech | Phase 1 | 11 |